✦ LIBER ✦

Phase II trial of ZD1694 (TomudexTM) in patients with advanced pancreatic cancer

✍ Scribed by Richard Pazdur; Neal J. Meropol; Ephraim S. Casper; C. Fuchs; Harold O. Douglass; Mark Vincent; James L. Abbruzzese

Publisher: Springer US
Year: 1995
Tongue: English
Weight: 285 KB
Volume: 13
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00873144

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II trial of edatrexate in patients

Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma

✍ Ephraim S. Casper; Gary K. Schwartz; Bruce Johnson; David P. Kelsen 📂 Article 📅 1992 🏛 Springer US 🌐 English ⚖ 293 KB

Phase II trial of gemcitabine in patient

Phase II trial of gemcitabine in patients with advanced gastric cancer

✍ Kathy Christman; David Kelsen; Leonard Saltz; Peter G. Tarassoff 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 327 KB 👁 3 views

Phase II trial of PALA in combination wi

Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer

✍ Elizabeth Rosyold; Russell Schilder; Judy Walczak; S. M. DiFino; P. J. Flynn; T. 📂 Article 📅 1992 🏛 Springer 🌐 English ⚖ 371 KB

Phase II trial of intravenous hexamethyl

Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer

✍ Mark D. Hauge; Harry J. Long; Lynn C. Hartmann; John H. Edmonson; Maurice J. Web 📂 Article 📅 1992 🏛 Springer US 🌐 English ⚖ 192 KB

Phase II trial of fazarabine (arabinofur

Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma

✍ Ephraim S. Casper; Gary K. Schwartz; David P. Kelsen 📂 Article 📅 1992 🏛 Springer US 🌐 English ⚖ 365 KB

Phase II trial of idarubicin in patients

Phase II trial of idarubicin in patients with advanced lymphoma

✍ Helen Gillies; Raymond Liang; Howard Rogers; Peter Harper; Liakat Parapia; Geoff 📂 Article 📅 1988 🏛 Springer 🌐 English ⚖ 377 KB

A phase II trial of idarubicin was performed in 24 patients with advanced lymphoma. The drug was administered in a dose of 10-15 mg/m2 i.v. or 15-70 mg/m2 p.o. (single dose) every 3 weeks. There were four partial responses and four minor responses. All but one of the responders had received prior do